PFE vs. REGN
PFE (Pfizer Inc.) and REGN (Regeneron Pharmaceuticals, Inc.) are both stocks. Both are in the Healthcare sector — PFE in Drug Manufacturers - General, REGN in Biotechnology. Over the past 10 years, PFE returned 1.92%/yr vs 4.61%/yr for REGN. At a 0.26 correlation, their price movements are largely independent.
Performance
PFE vs. REGN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PFE achieves a 6.63% return, which is significantly higher than REGN's -18.32% return. Over the past 10 years, PFE has underperformed REGN with an annualized return of 1.92%, while REGN has yielded a comparatively higher 4.61% annualized return.
PFE
- 1D
- 1.38%
- 1M
- -1.27%
- YTD
- 6.63%
- 6M
- 3.31%
- 1Y
- 17.51%
- 3Y*
- -7.13%
- 5Y*
- -3.25%
- 10Y*
- 1.92%
REGN
- 1D
- 1.58%
- 1M
- -10.34%
- YTD
- -18.32%
- 6M
- -12.78%
- 1Y
- 30.36%
- 3Y*
- -5.46%
- 5Y*
- 4.37%
- 10Y*
- 4.61%
PFE vs. REGN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
PFE Pfizer Inc. | 6.63% | 0.65% | -2.22% | -41.26% | -10.41% | 66.70% | 3.07% | -6.91% | 24.82% | 15.90% |
REGN Regeneron Pharmaceuticals, Inc. | -18.32% | 8.96% | -18.90% | 21.73% | 14.25% | 30.72% | 28.66% | 0.53% | -0.65% | 2.42% |
Correlation
The correlation between PFE and REGN is 0.44, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.44 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.37 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.39 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.37 |
Correlation (All Time) Calculated using the full available price history since Apr 3, 1991 | 0.26 |
The correlation between PFE and REGN shifts across timeframes, from 0.26 (all time) to 0.44 (1 year), reflecting how their relationship changes across market environments.
Fundamentals
PFE:
$147.23B
REGN:
$67.71B
PFE:
$1.31
REGN:
$41.05
PFE:
19.58
REGN:
15.32
PFE:
2.32
REGN:
4.54
PFE:
1.63
REGN:
2.15
PFE:
$63.32B
REGN:
$14.92B
PFE:
$43.91B
REGN:
$12.61B
PFE:
$16.94B
REGN:
$5.74B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PFE vs. REGN — Risk / Return Rank
PFE
REGN
PFE vs. REGN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Pfizer Inc. (PFE) and Regeneron Pharmaceuticals, Inc. (REGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| PFE | REGN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.19 | ||
| Sortino ratioReturn per unit of downside risk | -0.23 | ||
| Omega ratioGain probability vs. loss probability | 1.15 | 1.18 | -0.04 |
| Calmar ratioReturn relative to maximum drawdown | 1.53 | 1.18 | +0.35 |
| Martin ratioReturn relative to average drawdown | 3.15 | 4.09 | -0.94 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| PFE | REGN | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.74 | 0.93 | -0.19 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.13 | 0.14 | -0.27 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.08 | 0.14 | -0.06 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.33 | 0.16 | +0.17 |
Drawdowns
PFE vs. REGN - Drawdown Comparison
The maximum PFE drawdown since its inception was -69.24%, smaller than the maximum REGN drawdown of -91.81%. Use the drawdown chart below to compare losses from any high point for PFE and REGN.
Loading charts...
Drawdown Indicators
| PFE | REGN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -69.24% | -91.81% | +22.57% |
Max Drawdown (1Y)Largest decline over 1 year | -11.47% | -25.85% | +14.38% |
Max Drawdown (3Y)Largest decline over 3 years | -40.75% | -59.69% | +18.94% |
Max Drawdown (5Y)Largest decline over 5 years | -58.96% | -59.69% | +0.73% |
Max Drawdown (10Y)Largest decline over 10 years | -58.96% | -59.69% | +0.73% |
Current DrawdownCurrent decline from peak | -46.76% | -47.25% | +0.49% |
Average DrawdownAverage peak-to-trough decline | -22.89% | -42.39% | +19.50% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.57% | 7.45% | -1.88% |
Volatility
PFE vs. REGN - Volatility Comparison
The current volatility for Pfizer Inc. (PFE) is 4.28%, while Regeneron Pharmaceuticals, Inc. (REGN) has a volatility of 12.54%. This indicates that PFE experiences smaller price fluctuations and is considered to be less risky than REGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PFE | REGN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 4.28% | 12.54% | -8.26% |
Volatility (6M)Calculated over the trailing 6-month period | 14.69% | 22.39% | -7.70% |
Volatility (1Y)Calculated over the trailing 1-year period | 23.88% | 32.85% | -8.97% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 25.50% | 30.77% | -5.27% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 23.88% | 32.16% | -8.28% |
Dividends
PFE vs. REGN - Dividend Comparison
PFE's dividend yield for the trailing twelve months is around 6.70%, more than REGN's 0.58% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
PFE Pfizer Inc. | 6.70% | 6.91% | 6.33% | 5.70% | 3.12% | 2.64% | 3.92% | 3.68% | 3.12% | 3.53% | 3.69% | 3.47% |
REGN Regeneron Pharmaceuticals, Inc. | 0.58% | 0.46% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Financials
PFE vs. REGN - Financials Comparison
This section allows you to compare key financial metrics between Pfizer Inc. and Regeneron Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
PFE vs. REGN - Profitability Comparison
PFE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a gross profit of 9.72B and revenue of 14.45B. Therefore, the gross margin over that period was 67.3%.
REGN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a gross profit of 2.94B and revenue of 3.61B. Therefore, the gross margin over that period was 81.4%.
PFE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported an operating income of 4.03B and revenue of 14.45B, resulting in an operating margin of 27.9%.
REGN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported an operating income of 642.90M and revenue of 3.61B, resulting in an operating margin of 17.8%.
PFE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a net income of 2.69B and revenue of 14.45B, resulting in a net margin of 18.6%.
REGN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a net income of 727.20M and revenue of 3.61B, resulting in a net margin of 20.2%.
Frequently Asked Questions
PFE and REGN have a correlation of 0.44, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
REGN has higher volatility (12.54%) compared to PFE (4.28%). In terms of maximum drawdown, PFE dropped -69.24% vs REGN's -91.81%.
REGN currently has the higher Sharpe Ratio (0.93 vs 0.74), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PFE and REGN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer